Report 1-year follow-up data from the LAPC pilot trial
Deadline passed; outcome being checked
- Announced
- 6 Jan 2021
- Due
- 31 Dec 2021
- Status
- Checking
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“LAPC Pilot 1 Year Follow-up (3) Pancreatic Cancer Increasing GC4419 vs. placebo 2H 2021”
What we found
The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 6 Jan 2021
Deadline 31 Dec 2021 (“2H 2021”) · target 1 year
-
Version 2 · stated 11 Mar 2021
Deadline 31 Dec 2021 (“in the second half of 2021”) · wording expected
“The Company plans to provide final data from this trial with at least one year of follow-up data on all patients in the second half of 2021.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- LAPC pilot 1-year follow-up data
- Target
- 1 year
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Galera Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C563577-021134 · Corrections policy